$22.12
0.25[1.14%]
At close: Apr 26
$22.12
0[0.00%]
After Hours: 4:20PM EDT
Arrowhead Pharma
(NASDAQ:ARWR)Latest News for Arrowhead Pharma Stock (NASDAQ:ARWR)
Arrowhead Pharma Stock (NASDAQ: ARWR)
Categories: All
Monday, April 08, 2024
Thursday, April 04, 2024
Monday, March 25, 2024
Monday, March 11, 2024
Friday, March 08, 2024
- Arrowhead Pharmaceuticals shares are trading higher after the company announced that it initiated its Phase 1/2a study of ARO-DM1 for the treatment of type 1 myotonic dystrophy.Benzinga Newsdesk - Mar 8, 2024, 10:36AM
- Arrowhead Pharmaceuticals Says It Initiated Phase 1/2a Study Of ARO-DM1 For Treatment Of Type 1 Myotonic Dystrophy, Company Adds ARO-DM1 Is Designed To Reduce Expression Of Dystrophia Myotonica Protein Kinase (DMPK) Gene In MuscleBenzinga Newsdesk - Mar 8, 2024, 7:34AM
Friday, March 01, 2024
Wednesday, February 28, 2024
- Blog Chatter Suggests "People Following The Situation Have Heard Speculation Arrowhead Pharmaceuticals Recently Rebuffed An Indicative Approach Pitched At Around $45 A Share."; Shares Spiking HigherBenzinga Newsdesk - Feb 28, 2024, 1:20PM
- Watching Arrowhead Pharmaceuticals; Traders Circulating M&A Blog Chatter Sugging The Company Is Seeing Takeover InterestBenzinga Newsdesk - Feb 28, 2024, 1:18PM
Thursday, February 08, 2024
Wednesday, February 07, 2024
- Citigroup Maintains Neutral on Arrowhead Pharma, Raises Price Target to $34Benzinga Newsdesk - Feb 7, 2024, 2:07PM
- Cracking The Code: Understanding Analyst Reviews For Arrowhead PharmaBenzinga Insights - Feb 7, 2024, 12:01PM
- RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $50 Price TargetBenzinga Newsdesk - Feb 7, 2024, 11:55AM
- Arrowhead Pharma shares are trading lower after the company reported worse-than-expected Q1 financial results.Benzinga Newsdesk - Feb 7, 2024, 8:26AM
Tuesday, February 06, 2024
- Arrowhead Pharma shares are trading lower after the company reported worse-than-expected Q1 financial results.Benzinga Newsdesk - Feb 6, 2024, 4:37PM
- 12 Health Care Stocks Moving In Tuesday's After-Market SessionBenzinga Insights - Feb 6, 2024, 4:31PM
- Recap: Arrowhead Pharma Q1 EarningsBenzinga Insights - Feb 6, 2024, 4:10PM
- Arrowhead Pharma Q1 EPS $(1.24) Misses $(0.82) Estimate, Sales $3.55M Miss $29.51M EstimateBenzinga Newsdesk - Feb 6, 2024, 4:07PM
- Earnings Scheduled For February 6, 2024Benzinga Insights - Feb 6, 2024, 5:42AM
Tuesday, January 16, 2024
Thursday, January 04, 2024
Wednesday, January 03, 2024
- Why SoFi Technologies Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionAvi Kapoor - Jan 3, 2024, 12:58PM
- Why Arrowhead Pharmaceuticals Shares Are MovingHenry Khederian - Jan 3, 2024, 10:30AM
- TDCX Receives Preliminary Non-binding Proposal Letter, Joins Pure Storage, Dyne Therapeutics And Other Big Stocks Moving Higher On WednesdayAvi Kapoor - Jan 3, 2024, 10:24AM
- Arrowhead Pharmaceuticals Reports Pricing Of Offering Of 15.79M Shares At $28.50 Per Share; Gross Offering Proceeds Will Be Approximately $450MBenzinga Newsdesk - Jan 3, 2024, 7:01AM
Tuesday, January 02, 2024
Friday, December 29, 2023
Thursday, December 21, 2023
Monday, December 04, 2023
Thursday, November 30, 2023
- Why Titan Machinery Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionLisa Levin - Nov 30, 2023, 1:13PM
- Arrowhead Pharmaceuticals shares are trading lower after the company reported FY23 results.Benzinga Newsdesk - Nov 30, 2023, 10:37AM
- Morgan Stanley Maintains Equal-Weight on Arrowhead Pharma, Lowers Price Target to $37Benzinga Newsdesk - Nov 30, 2023, 10:14AM
- RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $50 Price TargetBenzinga Newsdesk - Nov 30, 2023, 9:54AM
Wednesday, November 29, 2023
- Recap: Arrowhead Pharma Q4 EarningsBenzinga Insights - Nov 29, 2023, 4:45PM
- Arrowhead Pharmaceuticals Reports FY23 EPS Of $(1.92) Vs (1.67) Last Year; Revenue $240.735M Vs $243.23M Last YearBenzinga Newsdesk - Nov 29, 2023, 4:05PM
- Earnings Scheduled For November 29, 2023Benzinga Insights - Nov 29, 2023, 7:46AM
Tuesday, November 28, 2023
- Earnings Outlook For Arrowhead PharmaBenzinga Insights - Nov 28, 2023, 9:01AM
- Arrowhead Pharmaceuticals Has Filed An Application For Clearance To Initiate A Phase 1/2A Trial Of ARO-DM1 In New Zealand For Type 1 Myotonic Dystrophy, The Most Common Adult-onset Muscular DystrophyBenzinga Newsdesk - Nov 28, 2023, 7:32AM
Monday, November 13, 2023
Tuesday, October 31, 2023
Thursday, September 21, 2023
Tuesday, September 19, 2023
- Analyst Expectations for Arrowhead Pharma's FutureBenzinga Insights - Sep 19, 2023, 11:00AM
- Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2023Benzinga Insights - Sep 19, 2023, 11:00AM
- Citigroup Initiates Coverage On Arrowhead Pharma with Neutral Rating, Announces Price Target of $33Benzinga Newsdesk - Sep 19, 2023, 5:47AM